ACTRN12617000540314暂停2 期
Efficacy of Epidermal Growth Factor Receptor (EGFR) inhibitor Panitumumab for the treatment of KRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinoma
Dr Daniel Croagh0 个研究点目标入组 24 人开始时间: 2017年4月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •i.Adults, age 18 years or over, male or female
- •ii.Locally advanced (unresectable), recurrent or metastatic biopsy-proven PDAC (note: patients with ampullary and peri-ampullary tumours will also be allowed, providing they meet all other inclusion criteria)
- •iii.KRAS wild-type PDAC (for panitumumab treatment arm)
- •iv.ECOG performance status 0-2
- •v.Measurable disease as per the response evaluation criteria in RECIST guideline version 1.1
- •vi.Progressive disease following first line chemotherapy - defined as an increase in CA 19.9 of 30% above that recorded at the end of first line therapy (confirmed on 2 blood draws) or evidence of progressive disease on standard imaging using CT scans.
- •vii.Patients whose tumours recur within 12 months of the completion of adjuvant chemotherapy and are otherwise eligible for this study will be considered to have received first line chemotherapy” for the purposes of this study. Patients who have received more than one line of chemotherapy may be considered on an individual basis, if they meet all other eligibility criteria.
- •viii.Adequate bone marrow function; (ANC more than or equal to 1500/mcL, platelets more than or equal to 100 000/mcL, haemoglobin more than or equal to 9g/dL)
- •ix.Adequate renal function; calculated creatinine clearance (CrCl) greater than or equal to 50ml/min (Cockcroft-Gault formula) or Creatinine less than or equal to 1.5 XULN
- •x.Adequate hepatic function; serum total bilirubin less than or equal to 1.5 times ULN, ALT/AST less than or equal to 2.5 times ULN (or less than or equal to 5 times ULN with documented liver metastases), ALP less than or equal to 5 times ULN, and INR less than or equal to 1.5
- •xi.Provision of informed consent for participation in the study
排除标准
- •i.Pancreatic neuroendocrine tumours, cholangiocarcinoma affecting the supra-pancreatic bile duct and tumours metastatic to the pancreas (e.g. renal cell carcinoma)
- •ii.Children, persons younger than 18 years of age
- •iii.Pregnancy or lactation
- •iv.Active or uncontrolled infection
- •v.Previous treatment with EGFR inhibitor
- •vi.Previous radiotherapy to the pancreas if this is the only site of measurable disease (unless there is demonstrated, clear evidence of radiological progression at the site since the completion of radiotherapy).
- •vii.Hypersensitivity to study drug
- •viii.Previous or current interstitial lung disease
- •ix.Previous or current pulmonary fibrosis
- •x.History of another malignancy within 2 years prior to allocation. (NB. Patients with adequately treated carcinoma in-situ, curatively treated uterine cervix carcinoma in-situ or non-melanoma skin carcinoma, or superficial transitional cell carcinoma of the bladder remain eligible even if diagnosed less than 2 years earlier. Patients with a history of other malignancy are eligible if they have been continuously disease-free for at least 2 years following definitive treatment.)
- •xi.Any severe or uncontrolled medical conditions within 3 months prior to allocation, including but not limited to:
- •Unstable cardiac disease, myocardial infarction or uncontrolled arrhythmia
- •Cirrhosis, active or chronic Hepatitis B infection, Hepatitis C infection, HIV seropositivity
- •Active bleeding diathesis
- •Renal failure
- •Unstable diabetes
研究者
相似试验
撤回
2 期
The Effects of Epidermal Growth Factor Receptor (EGFR) Inhibition on Pulmonary Arterial Hypertension Associated with Systemic Sclerosis A phase II controlled open-label safety and efficacy study.high pulmonary vascular pressure associated with scleroderma100192801001076110037454NL-OMON30491Vrije Universiteit Medisch Centrum20
已完成
不适用
The effects of epidermal growth factor receptor inhibition on pulmonary arterial hypertension associated with systemic sclerosisSclerosis-associated Pulmonary Arterial Hypertension (SScPAH)Circulatory SystemPulmonary Arterial HypertensionISRCTN75611179VU University Medical Centre (The Netherlands)20
已完成
1 期
A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, PaclitaxelLoaded EnGeneIC Delivery Vehicles (Erbitux®EDVsPac) in Patients with Advanced SolidTumoursAdvanced Solid TumoursCancer - Other cancer typesACTRN12609000672257EnGeneIC Pty Ltd32
招募中
不适用
ung Cancer Epidermal Growth Factor (EGFR) Gene Mutation Testing in New Zealandung cancerCancer - Lung - Non small cellLung cancerACTRN12615000998549Auckland UniServices Ltd2,000
暂停
不适用
The Effects of Epidermal Growth Factor (EGFR) Inhibition on Pulmonary Arterial Hypertension Associated with Systemic Sclerosis.18-year old patients with systemic sclerosis-associated pulmonary arterial hypertension (SScPAH)NL-OMON27131VU University Medical Center20